FibroGen, Inc (NASDAQ:FGEN) VP Pat Cotroneo sold 5,500 shares of FibroGen stock in a transaction on Monday, June 19th. The stock was sold at an average price of $30.00, for a total transaction of $165,000.00. Following the transaction, the vice president now owns 168,866 shares in the company, valued at approximately $5,065,980. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Pat Cotroneo also recently made the following trade(s):

  • On Thursday, June 22nd, Pat Cotroneo sold 3,000 shares of FibroGen stock. The stock was sold at an average price of $32.00, for a total transaction of $96,000.00.
  • On Monday, June 12th, Pat Cotroneo sold 2,891 shares of FibroGen stock. The stock was sold at an average price of $28.75, for a total transaction of $83,116.25.
  • On Tuesday, April 25th, Pat Cotroneo sold 6,500 shares of FibroGen stock. The stock was sold at an average price of $28.00, for a total transaction of $182,000.00.

Shares of FibroGen, Inc (NASDAQ:FGEN) traded up 0.47% during trading on Monday, hitting $32.40. 337,126 shares of the stock were exchanged. FibroGen, Inc has a 52 week low of $14.50 and a 52 week high of $33.40. The firm’s market capitalization is $2.27 billion. The stock’s 50 day moving average price is $27.99 and its 200 day moving average price is $25.07.

FibroGen (NASDAQ:FGEN) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.11. FibroGen had a negative net margin of 37.60% and a negative return on equity of 36.41%. The company had revenue of $26.89 million for the quarter, compared to analyst estimates of $26.02 million. On average, equities analysts predict that FibroGen, Inc will post ($1.81) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/06/26/fibrogen-inc-fgen-vp-sells-165000-00-in-stock.html.

Several institutional investors have recently added to or reduced their stakes in FGEN. Capital Impact Advisors LLC raised its position in FibroGen by 8.7% in the first quarter. Capital Impact Advisors LLC now owns 46,710 shares of the biopharmaceutical company’s stock valued at $1,151,000 after buying an additional 3,727 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in FibroGen during the first quarter valued at approximately $574,000. Woodstock Corp raised its position in FibroGen by 42.9% in the first quarter. Woodstock Corp now owns 28,415 shares of the biopharmaceutical company’s stock valued at $700,000 after buying an additional 8,526 shares in the last quarter. Teachers Advisors LLC raised its position in FibroGen by 3.7% in the fourth quarter. Teachers Advisors LLC now owns 461,901 shares of the biopharmaceutical company’s stock valued at $9,885,000 after buying an additional 16,544 shares in the last quarter. Finally, Norges Bank acquired a new position in FibroGen during the fourth quarter valued at approximately $8,480,000. 43.85% of the stock is currently owned by institutional investors.

A number of equities analysts have recently commented on the stock. William Blair reiterated an “outperform” rating on shares of FibroGen in a report on Monday. BidaskClub upgraded shares of FibroGen from a “buy” rating to a “strong-buy” rating in a report on Saturday. Stifel Nicolaus reiterated a “buy” rating and set a $38.00 price target (up previously from $32.00) on shares of FibroGen in a report on Thursday. Finally, Zacks Investment Research lowered shares of FibroGen from a “hold” rating to a “sell” rating in a report on Monday, May 8th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $38.75.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.